Unknown

Dataset Information

A real-world pharmacovigilance study of FDA adverse event reporting system events for Lutetium-177-PSMA-617.


ABSTRACT: Lutetium-177(177Lu)-PSMA-617 has been approved for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Our main objective is to elucidate the association between 177Lu-PSMA-617 and reported adverse events (AEs) in the FDA Adverse Event Reporting System (FAERS) database. Relevant information regarding 177Lu-PSMA-617 usage and reports of AEs was extracted from the FAERS database. The Empirical Bayes Geometric Mean (EBGM), Proportional Reporting Ratio (PRR), Reporting Odds Ratio (ROR), and Bayesian Confidence Propagation Neural Network (BCPNN) with their 95% confidence intervals (CI) were calculated using four algorithms of disproportionality analysis. The pharmacovigilance signals deemed significant across the four algorithms were consid

SUBMITTER: Wu S 

PROVIDER: S-EPMC11519899 | biostudies-literature | 2024 Oct

REPOSITORIES: biostudies-literature